checkAd

    DGAP-News  140  0 Kommentare Aladdin Healthcare Technologies completes AI-driven Drug Discovery Platform (AIDD) for Commercial Use in Drug Development - Seite 3

    Website Link: www.aladdinid.com
    GSIN: A12ULL
    ISIN: DE000A12ULL2
    TICKER SYMBOL: NMI

    For further information:

    Aladdin Healthcare Technologies Ltd.
    24-26 Baltic Street West
    London EC1Y 0UR
    Phone +44 7714 719696
    Email: info@aladdinid.com

    Contact Press
    CROSS ALLIANCE communication GmbH
    Sara Pinto
    Phone +49 89 1250 90330
    Email: pi@crossalliance.de
    www.crossalliance.de


    08.10.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
    The issuer is solely responsible for the content of this announcement.

    The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
    Archive at www.dgap.de

    Language: English
    Company: Aladdin Healthcare Technologies SE
    Unter den Linden 10
    10117 Berlin
    Germany
    Phone: 030 700140449
    E-mail: info@aladdinid.com
    Internet: www.aladdinid.com
    ISIN: DE000A12ULL2
    WKN: A12ULL
    Listed: Regulated Market in Dusseldorf
    EQS News ID: 1139561

     
    End of News DGAP News Service

    Lesen Sie auch

    1139561  08.10.2020 

    fncls.ssp?fn=show_t_gif&application_id=1139561&application_name=news&site_id=wallstreet
    Seite 3 von 3



    EQS Group AG
    0 Follower
    Autor folgen
    RSS-Feed abonnieren

    Weitere Artikel des Autors


    Verfasst von EQS Group AG
    1 im Artikel enthaltener WertIm Artikel enthaltene Werte
    DGAP-News Aladdin Healthcare Technologies completes AI-driven Drug Discovery Platform (AIDD) for Commercial Use in Drug Development - Seite 3 DGAP-News: Aladdin Healthcare Technologies SE / Key word(s): Product Launch Aladdin Healthcare Technologies completes AI-driven Drug Discovery Platform (AIDD) for Commercial Use in Drug Development 08.10.2020 / 08:09 The issuer is solely …